Congress demands final sunscreen monograph
This article was originally published in The Rose Sheet
Executive SummaryRep. Nita Lowey, D-N.Y., reintroduces the "Skin Cancer Prevention, Education, and Consumer Right-To-Know Act." H.R. 2088 would bring into force FDA's proposed rule amending the final sunscreen monograph - notwithstanding "any other provision of law" - 180 days after the bill's enactment. FDA's draft rule includes formulation, testing and labeling requirements to ensure consumers are protected against ultraviolet A as well as ultraviolet B radiation. Publication of the final sunscreen monograph, issued in 1999, has been repeatedly stayed due to industry pressure; in its December 2007 comments to the agency, industry groups opposed FDA's proposed 4-star rating system for UVA protection, which consumers could wrongly interpret to signify a product's overall effectiveness (1"The Rose Sheet" Jan. 14, 2008, p. 3). Meanwhile Ciba Corporation, whose Tinosorb M and Tinosorb S broad-spectrum sunscreen actives are marketed overseas - as well as companies interested in formulating with the ingredients - have been pressuring FDA to complete its "stagnant" review of UV filters, which would give U.S. consumers the same protection options enjoyed by the rest of the world (2"The Rose Sheet" Dec. 8, 2008, p. 4). More than 1 mil. new cases of skin cancer are diagnosed in the U.S. each year, H.R. 2088 notes. Bill has been referred to the Energy and Commerce Committee
You may also be interested in...
As of 5 February, the Scientific Committee on Consumer Safety is evaluating use of titanium dioxide – now officially classified as a Category 2 carcinogen in the EU – in cosmetic products that can expose consumers by way of inhalation. Without a favorable SCCS opinion, the ingredient’s use in those contexts will be banned under Article 15 of the Cosmetics Regulation.